Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib - Related Studies

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

This study is currently recruiting participants.

Study NCT00688766. Last updated on December 2, 2008. Information provided by Infinity Pharmaceuticals

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Gastrointestinal Stromal Tumors

2	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Neoplasms
		Neoplasms by Site

3	Interventions listed in this trial
		placebo

4	Additional drug interventions recognized in this trial
		Sunitinib

5	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antineoplastic Agents
		Growth Inhibitors
		Growth Substances
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Infinity Pharmaceuticals
		MedImmune LLC
		AstraZeneca